Evidence-Based Positron Emission Tomography : Summary of Recent Meta-Analyses on PET.
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | eBook |
| Language: | English |
| Published: |
Cham :
Springer International Publishing AG,
2020.
|
| Edition: | 1st ed. |
| Subjects: | |
| Online Access: | Click to View |
Table of Contents:
- Intro
- Preface
- Contents
- Part I: Introduction
- 1: Introduction to Different PET Radiopharmaceuticals and Hybrid Modalities (PET/CT and PET/MRI)
- 1.1 Physical Principles of Positron Emission Tomography and Hybrid Modalities
- 1.2 Hybrid Scanners: PET/CT and PET/MRI
- 1.3 Positron Emission Tomography Radiopharmaceuticals
- References
- 2: A Practical Guideline on Diagnostic and Prognostic Meta-Analyses
- 2.1 Introduction
- 2.2 A Clear Topic for Systematic Review: Formulating the Question
- 2.3 Which Articles Should Be Included? Search Strategy, Inclusion and Exclusion Criteria
- 2.4 Quality Assessment of the Included Studies
- 2.5 Data Extraction
- 2.6 Pooling Diagnostic Indices Across Studies and Reporting Heterogeneity
- 2.7 Discussion and Conclusion of Systematic Reviews
- 2.8 Final Comment
- References
- Part II: Evidence-Based PET in Oncology
- 3: Evidence-Based PET for Brain Tumours
- 3.1 Background
- 3.2 Evaluation of Suspicious Primary Brain Tumour
- 3.2.1 18F-FDG
- 3.2.2 11C-Methionine
- 3.2.3 18F-FET
- 3.2.4 18F-FDOPA
- 3.3 Glioma Grading
- 3.3.1 18F-FDG
- 3.3.2 11C-Methionine
- 3.3.3 18F-FET
- 3.3.4 18F-FDOPA
- 3.4 Delineation of Gliomas
- 3.5 Diagnosis of Recurrent Brain Tumours
- 3.5.1 18F-FDG
- 3.5.2 11C-Methionine
- 3.5.3 18F-FET
- 3.5.4 18F-FDOPA
- 3.5.5 18F-FLT
- 3.5.6 18C-Choline
- 3.6 Diagnosis of Brain Metastases
- 3.7 Diagnosis of Recurrent Brain Metastases
- 3.8 Diagnosis of Primary Central Nervous System Lymphoma (PCNSL)
- 3.9 Prognostic Value in Patients with Glioma
- 3.10 Conclusions
- References
- 4: Evidence-Based PET for Head and Neck Tumours
- 4.1 Introduction
- 4.2 Staging
- 4.2.1 T Staging
- 4.2.2 Nodal and Distant Metastases Detection
- 4.3 Prognostic Value
- 4.4 Post-treatment Evaluation.
- 4.5 Carcinoma of Unknown Origin and Incidental Findings
- References
- 5: Evidence-Based PET for Thoracic Tumours
- 5.1 Introduction
- 5.2 Evidence-Based Data on PET in Primary Lung Tumours
- 5.2.1 Characterization of Solitary Pulmonary Nodules (SPNs)
- 5.2.1.1 Single-Time-Point 18F-FDG PET or PET/CT
- 5.2.1.2 Dual-Time-Point (DTP) PET
- 5.2.1.3 18F-FLT PET for Evaluation of Pulmonary Lesions
- 5.2.2 NSCLC Staging
- 5.2.2.1 N Staging
- 5.2.2.2 M Staging
- 5.2.3 Restaging After Induction Therapy and Prediction of Treatment Response
- 5.2.4 Radiation Therapy Pretreatment Planning in NSCLC
- 5.2.5 Diagnosis of Lung Cancer Recurrence
- 5.2.6 Prognostic Evaluation in NSCLC
- 5.2.7 Management of SCLC
- 5.3 Evidence-Based Data on PET in Pleural Tumours
- 5.4 Evidence-Based Data on PET in Thymic Epithelial Tumours
- 5.5 Evidence-Based Data on PET in Esophageal Tumours
- 5.5.1 Staging
- 5.5.2 Restaging
- 5.5.3 Predictive and Prognostic Value
- References
- 6: Evidence-Based PET for Breast Cancer
- 6.1 Introduction
- 6.2 Staging
- 6.3 Restaging and Assessment of Response to Neoadjuvant Therapy
- 6.4 Prognostic Value
- 6.5 Incidental 18F-FDG Uptake
- 6.6 18F-FDG Positron Emission Mammography
- 6.7 PET/MRI
- 6.8 Other PET Tracers Beyond 18F-FDG
- References
- 7: Evidence-Based PET for Abdominal and Pelvic Tumours
- 7.1 Introduction
- 7.2 PET in Gastrointestinal Tumours
- 7.2.1 Colorectal Cancer
- 7.2.2 Gastric Cancer
- 7.2.3 Anal Cancer
- 7.2.4 Stromal Tumours (GIST)
- 7.2.5 Hepato-biliary Tumours
- 7.2.6 Liver Metastases
- 7.2.7 Pancreatic Cancer
- 7.3 PET in Gynaecological Tumours
- 7.3.1 Cervical Cancer
- 7.3.2 Endometrial Cancer
- 7.3.3 Ovarian Cancer
- 7.3.4 Peritoneal Carcinomatosis
- 7.3.5 PET/MRI
- 7.4 PET in Uro-genital Tumours
- 7.4.1 Prostate Cancer.
- 7.4.1.1 Radiolabelled Choline PET for Prostate Cancer
- 7.4.1.2 Radiolabelled PSMA PET in Prostate Cancer
- 7.4.1.3 Fluciclovine PET in Prostate Cancer
- 7.4.1.4 Incidental 18F-FDG Uptake in the Prostate
- 7.4.2 Bladder Cancer
- 7.4.3 Renal Cell Carcinoma
- 7.4.4 Testicular and Penile Cancer
- References
- 8: Evidence-Based PET for Cutaneous, Musculoskeletal and Unknown Primary Tumours
- 8.1 Introduction
- 8.2 PET in Malignant Melanoma
- 8.2.1 Introduction
- 8.2.2 Staging
- 8.2.3 Restaging and Treatment Monitoring
- 8.3 PET in Sarcomas
- 8.3.1 Introduction
- 8.3.2 Staging
- 8.3.3 Restaging and Treatment Monitoring
- 8.4 PET for Bone Metastases
- 8.4.1 Introduction
- 8.4.2 Detection of Bone Metastases
- 8.5 PET for Cancer of Unknown Primary (CUP) and Paraneoplastic Syndromes
- 8.5.1 Introduction
- 8.5.2 Impact of PET in Patients with CUP
- 8.5.3 Impact of PET in Patients with Paraneoplastic Syndromes
- References
- 9: Evidence-Based PET for Haematological Tumours
- 9.1 Introduction
- 9.2 18F-FDG PET or PET/CT in Staging or Detection
- 9.2.1 Post-transplant Lymphoproliferative Disorder
- 9.2.2 Follicular Lymphoma
- 9.2.3 Marginal Zone Lymphoma of the Mucosa-Associated Lymphoid Tissue
- 9.2.4 Bone Marrow Involvement in Lymphoma
- 9.2.5 Natural Killer/T-Cell Lymphoma
- 9.2.6 Multiple Myeloma
- 9.3 18F-FDG PET or PET/CT in Treatment Response Evaluation (Interim and/or End of Therapy)
- 9.3.1 Post-transplant Lymphoproliferative Disorder
- 9.3.2 Hodgkin and Non-Hodgkin Lymphomas
- 9.4 18F-FDG PET or PET/CT in Prognosis/Outcome Evaluation
- 9.4.1 Hodgkin and Non-Hodgkin Lymphomas
- 9.4.2 Multiple Myeloma
- 9.5 Prognostic Role of Semi-quantitative PET Parameters
- 9.6 18F-FDG PET or PET/CT in Comparison with Magnetic Resonance Imaging
- 9.7 Conclusions
- References.
- 10: Evidence-Based PET for Endocrine Tumours and Disorders
- 10.1 Introduction
- 10.2 Adrenal Tumours and Paragangliomas
- 10.2.1 Characterization of Adrenal Masses
- 10.2.2 Paragangliomas
- 10.3 Neuroblastoma
- 10.4 Merkel Cell Carcinoma
- 10.5 Gastroenteropancreatic and Pulmonary Neuroendocrine Tumours
- 10.6 Congenital Hyperinsulinism
- 10.7 Thyroid Diseases
- 10.7.1 Thyroid Incidentalomas
- 10.7.2 Indeterminate Thyroid Nodules
- 10.7.3 Recurrence of Differentiated Thyroid Cancer
- 10.7.4 Recurrence of Medullary Thyroid Cancer
- 10.8 Parathyroid Diseases
- References
- Part III: Evidence-Based PET in Cardiology
- 11: Evidence-Based PET for Cardiac Diseases
- 11.1 Introduction
- 11.2 Myocardial Blood Flow Perfusion
- 11.2.1 Performance of PET/CT in the Assessment of Myocardial Perfusion in Comparison to Other Myocardial Perfusion Imaging Modalities
- 11.2.2 Prognostic Value of Myocardial PET
- 11.3 Assessment of Myocardial Viability
- 11.4 Microvascular Disease
- 11.5 Cardiac Hybrid Imaging
- 11.6 Cardiac Amyloidosis
- References
- Part IV: Evidence-Based PET in Infection and Inflammation
- 12: Evidence-Based PET for Infectious and Inflammatory Diseases
- 12.1 Introduction
- 12.2 Fever of Unknown Origin (FUO)
- 12.3 Large Vessel Vasculitis (LVV)
- 12.4 Infectious Endocarditis and Cardiovascular Implantable Electronic Device Infections
- 12.5 Vascular Graft Infections
- 12.6 Sarcoidosis
- 12.7 Musculoskeletal Infections
- 12.8 Inflammatory Rheumatic Diseases
- 12.9 Inflammatory Bowel Diseases
- References
- Part V: Evidence-Based PET in Neurology
- 13: Evidence-Based PET for Neurological Diseases
- 13.1 Introduction
- 13.2 Evidence-Based PET in Neurodegenerative Dementia
- 13.3 Evidence-Based PET for Movement Disorders
- 13.4 Evidence-Based PET for Psychiatric Disorders.
- 13.5 Conclusions
- References
- Part VI: Miscellaneous
- 14: Meta-Analyses on Technical Aspects of PET
- 14.1 Introduction
- 14.2 Factors Affecting 18F-FDG Uptake
- 14.3 Repeatability of the Quantitative Measurements
- 14.4 Dual-Time-Point Imaging
- 14.5 Correlation Between Proliferation Markers (Ki-67) and Tracer Uptake in Tumours
- 14.6 Correlation Between 18F-FDG SUVmax and ADC Values in Tumour Tissues
- 14.7 Diagnostic Performance of Hybrid Imaging in Oncology
- 14.8 Varia
- References.